Table 1.
Experimental Model | Species | Mn (Dosage/Concentration) | Cytotoxicity Mechanisms | Disease Model | References |
---|---|---|---|---|---|
Neural cell type | |||||
Microglia | Mouse (N9), Mouse (BV2) | MnCl2 (50–1000 µM) | ↑TNF-α, ↑ILs, ↑interferons ↑NF-κB activation | Mn toxicity | [93,125,128] |
Microglia | Mouse (N9), Rat | MnCl2 (30 µM) | ↑TNF-α, ↑IL-1β | Mn toxicity | [125,127] |
Microglia | Human (HMC3) | MnCl2 (250 µM) | ↑LRRK2 expression and kinase activity ↑ROS, ↑TNF-α, ↑apoptosis |
Mn toxicity | [131] |
Astrocytes | Mice | MnCl2 (0.1–10 µM) | ↑Cyclooxygenase 2, ↑iNOS, ↑NF-κB activation, ↑inflammation | Mn toxicity | [118,120,121,122] |
Astrocytes | Mouse | MnCl2 (50 µM) | ↑Inflammation, ↑iNOS, ↑NO | Mn toxicity | [123] |
Astrocytes | Rat, Mice | MnCl2 (5, 50 µM) | ↑TNF-α, ↑IL-1β, ↑iNOS | Mn toxicity | [20,118,124,125,126] |
Astrocytes | Rat, Human | MnCl2 (250 µM) | ↓Glutamate reuptake, ↓EAAT1/GLAST, ↓EAAT2/GLT-1, ↑YY1, ↑HDAC-YY1 interaction | Mn toxicity | [149,150] |
Astrocytes | Rat | MnCl2 (100–200 µM) | ↓Glutamate reuptake, ↓SOD activity, ↓GPx activity, ↑LDH release, ↑IL-6 | Mn toxicity | [99] |
Astrocytes | Rat | MnCl2 (100, 500, 1000 µM) | ↑F2-isoprostanes, ↑lipid peroxidation | Mn toxicity | [107] |
Astrocytes | Human (U87) | MnCl2 (400, 800, 2000 µM) | ↓Glutathione | Mn toxicity | [100] |
Neurons | |||||
Cortical Neuron | rat | MnCl2 (500 µM) | ↑ROS production, ↑F2-isoprostanes, ↓ATP production | Mn toxicity | [22] |
Dopaminergic | Human (SH-SY5Y) | MnCl2 (800 µM) | ↑ROS production, ↑lipid peroxidation, ↓ATP levels, ↓mitochondrial membrane potential | Mn toxicity; PD | [101] |
Dopaminergic | Human (SH-SY5Y) | MnCl2 (2–125 µM) | ↑DNA damage, ↑oxidative stress | Mn toxicity; PD | [23] |
Dopaminergic | Rat (N27) | MnCl2 (300 µM) | ↑Cytochrome c release, ↑caspase-3 activation, ↑DNA damage, ↑ROS, ↑apoptosis, ↑αSyn aggregation | Mn toxicity | [94] |
Dopaminergic | Rat (N27) | MnCl2 (10–5000 µM) | ↑ROS, ↑mitochondria damage, ↑apoptosis, ↑PKCδ activation | Mn toxicity | [95,96] |
Catecholaminergic/Dopaminergic | Mouse (CAD), Human (LUHMES) | MnCl2 (250 µM) | ↓TH, ↓REST, ↓NRF2, ↓catalase, ↓HO-1 ↑oxidative stress, ↑inflammation |
Mn toxicity; PD | [8] |
Dopaminergic | Rat (PC12) | MnCl2 (100 µM) | ↑TH phosphorylation, ↑cytotoxicity | Mn toxicity; PD | [141] |
Dopaminergic | C. elegans | MnCl2 (40 mM) | ↑oxidative stress | Mn toxicity; PD | [98] |
Cholinergic | Mouse (SN56) | MnCl2 (1–200 µM) | ↑Aβ peptides misfolding and aggregation | AD | [179] |
Neuron | Mouse, Rat | MnCl2 (100, 500, 1000 µM) | ↑F2-isoprostanes, ↑lipid peroxidation | Mn toxicity | [106] |
Neuron | Rat (PC12) | MnCl2 (100–500 µM) | ↑Tau phosphorylation, ↑impaired tau degradation/aggregation, ↑ERK/GSK-3β activation, ↑cytotoxicity | AD | [180] |
Dopaminergic | Rat (MES 23.5) | MnCl2 (200–600 µM) | ↑αSyn levels, ↑p38 activation, ↑NF-κB activation, ↑NO, ↑apoptosis | Mn toxicity; PD | [167] |
Organotypic Brain Slices | Rat | MnCl2 (400 µM) | ↑ROS, ↑apoptosis, ↑LDH release, ↓SOD activity, ↑αSyn levels | Mn toxicity; PD | [166] |
Dopaminergic | Human (SH-SY5Y) | MnCl2 (500 µM) | ↑Apoptosis, ↑caspase 3, ↑αSyn levels | Mn toxicity; PD | [169] |
Dopaminergic | Mouse (MN9D) | MnCl2 (300 μM) | ↑Exosome release, ↑cytotoxicity, ↑Rab27a | Mn toxicity | [172] |
Dopaminergic | Human (LUHMES), Mouse (MN9D) | MnCl2 (10 mM) | ↑αSyn misfolding, ↑αSyn release, ↑inflammation | Mn toxicity | [173] |
Brain regions | |||||
Striatum, brain stem | Rat | MnCl2 (25 mg/kg) | ↓Glutathione synthesis, ↓energy ↑hypoxanthine, ↑xanthine, ↑uric acid |
[102] | |
Basal ganglia | Human | NA | ↑Astrogliosis | Mn toxicity; PD | [117] |
Basal ganglia (Striatum); Substantia nigra | Rat (neonate, adult) | MnCl2 (10 mg/kg) | ↓DA levels | Mn toxicity; PD | [132,133] |
Striatum | Rat | Mn (100 mg/kg) | ↓DA levels and stores, ↓DA turnover, ↓DA release, ↑behavioral deficits | Mn toxicity; PD | [134,135,136] |
Globus pallidus (Striatum), Midbrain | Human | NA | ↑Mn levels, ↓DA transporter | Mn toxicity | [111] |
Striatum | Rat | MnCl2 (5–20 mg/kg, daily, 20 d) | ↑Motor deficits, ↑oxidative stress | Mn toxicity; PD | [21] |
Striatum | Rat | MnCl2 (0.5–2 µmol/µL) | ↑Excitotoxic lesions; ↑oxidative stress, ↑mitochondrial impairment | Mn toxicity | [146] |
Striatum | Rat | MnCl2 (1 mg/mL) | ↓ChAT, ↓ACh levels, | Mn toxicity | [155] |
Striatum | Mouse | MnCl2 (50, 100, and 200 μmol/kg) | ↑Autophagy dysregulation, ↑cell injury. ↑αSyn | Mn toxicity; PD | [168] |
Hippocampus | Mouse | MnCl2 (100 µmol/kg, 5×/week, 6 weeks) | ↑Impaired NMDA phosphorylation, ↑memory dysfunction, ↑αSyn dysregulation | Mn toxicity; AD | [148] |
Whole brain | Rat | MnCl2 (30 mg/kg) | ↓AChE, ↑oxidative and nitrosative stress, ↑intracellular Ca2+ accumulation | Mn toxicity | [154] |
Whole brain | Rat | MnCl2 (3 mg/mL) | ↓GABA, ↑seizure duration, ↓seizure threshold | Mn toxicity | [25] |
Forebrain | Rat | MnCl2 (10 mM) | ↓GABA uptake | Mn toxicity | [159] |
Thalamus | Rat | MnCl2 (1 g/L) | ↑GABA | Mn toxicity | [160] |
Substantia nigra | Mouse | MnCl2 (30 mg/kg, daily/3 wks) | ↓TH, ↓EAAT1/GLAST, ↓EAAT2/GLT-1, ↑YY1, ↑HDAC-YY1 interaction, ↑motor deficits, ↑microglial activation | Mn toxicity; PD | [8] |
Midbrain, cerebellum | Mouse | MnCl2 (10 mg/mL) | ↓ChAT, ↑impaired choline uptake | Mn toxicity; encephalopathy | [156] |
Hippocampus, cortex, and basal ganglia | Rat | MnCl2 | ↓Choline transporter, ↓choline uptake, ↓homovanillic acid | Mn toxicity | [157] |
Prefrontal cortex | Mouse | MnCl2 (5 mg/kg, daily/22 d) | ↓ACh activity, ↓nicotinic ACh receptors, ↑impaired spatial memory | Mn toxicity; AD | [158] |
Frontal Cortex | Nonhuman primate | Mn (3.3–5.0, 5.0–6.7, 8.3–10 mg Mn/kg) | ↑αSyn aggregation, ↑apoptosis | Mn toxicity; PD | [165] |
Frontal cortex | Nonhuman primate | NA | ↑Aβ precursor protein 1, ↑Aβ expression, ↑cytotoxicity | AD | [176,177] |
Parietal cortex | Human | NA | ↑Mn levels, ↑AD pathology, ↑impaired Aβ and ApoE function | AD | [174] |
Cerebral cortex, hippocampus | Mouse | MnCl2 (0.36 mg/mL, 5 mos.) | ↑Aβ expression, ↑β- and γ-secretase cleavage activities | AD | [178] |
Blood | Human | NA | ↑Mn levels, ↑impaired Aβ degradation/aggregation, ↑cognitive impairment | AD | [175] |
↑: increased. ↓: decreased. NA, not applicable/not available. CAD: Cath.a differentiated. LRRK2: leucine rich repeat kinase 2. LUHMES: Lund human mesencephalic. TNF-α: tumor necrosis factor alpha. NF-κB: nuclear factor kappa-light-chain enhancer of B cells. IL-1β: interleukin 1β. IL-6: interleukin 6. iNOS: inducible nitric oxide synthase. NO: nitric oxide SOD: superoxide dismutase. GPx: glutathione peroxidase. LDH: lactate dehydrogenase. ROS: reactive oxygen species. EAAT1/2: excitatory amino acid transporter 1/2. GLAST: glutamate aspartate transporter 1. GLT: glutamate transporter 1 PKC: protein kinase C. GSH: glutathione. NRF2: Nuclear factor erythroid 2-related factor 2. HO-1: Heme oxygenase-1. REST: repressor element-1 silencing transcription factor. TH: tyrosine hydroxylase. DA: dopamine. αSyn: α-synuclein. Aβ: amyloid-β. ApoE: apolipoprotein E. ChAT: choline acetyltransferase. ACh: acetylcholine. GABA: gamma aminobutyric acid. ERK: extracellular signal-regulated kinase: GSK-3β: HDAC: histone deacetylase. YY1: Yin Yang 1. NMDA: N-methyl D-aspartate. PD: Parkinson’s disease. AD: Alzheimer’s disease.